S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

$94.02
-2.44 (-2.53%)
(As of 02/26/2024 ET)
Today's Range
$91.46
$94.79
50-Day Range
$85.37
$115.44
52-Week Range
$62.55
$163.24
Volume
4.58 million shs
Average Volume
4.65 million shs
Market Capitalization
$35.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$128.69

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
38.1% Upside
$129.82 Price Target
Short Interest
Healthy
6.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.59mentions of Moderna in the last 14 days
Based on 64 Articles This Week
Insider Trading
Selling Shares
$10.73 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.62) to ($3.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.70 out of 5 stars

Medical Sector

63rd out of 942 stocks

Biological Products, Except Diagnostic Industry

11th out of 152 stocks


MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

Novavax’s dispute resolution and upcoming earnings call (MRNA)
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MRNA Apr 2024 130.000 call
MRNA Mar 2024 160.000 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MRNA Mar 2024 100.000 put
MRNA Mar 2024 122.000 call
MRNA Mar 2024 110.000 put
Moderna: Counting On Pipeline Too Much
Why Moderna Stock Is Jumping Today
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
2/26/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$129.82
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+37.8%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
15 Analysts

Profitability

Net Income
$-4,714,000,000.00
Pretax Margin
-57.56%

Debt

Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share

Miscellaneous

Free Float
321,422,000
Market Cap
$35.62 billion
Optionable
Optionable
Beta
1.69

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Moderna was last updated on Sunday, February 25, 2024 at 4:28 PM.














MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

15 Wall Street analysts have issued 12 month target prices for Moderna's shares. Their MRNA share price targets range from $60.00 to $231.00. On average, they anticipate the company's stock price to reach $129.82 in the next year. This suggests a possible upside of 38.1% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 at the start of the year. Since then, MRNA stock has decreased by 5.5% and is now trading at $94.02.
View the best growth stocks for 2024 here
.

Are investors shorting Moderna?

Moderna saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 20,880,000 shares, a decrease of 9.5% from the January 15th total of 23,070,000 shares. Based on an average daily trading volume, of 4,650,000 shares, the short-interest ratio is currently 4.5 days. Currently, 6.3% of the shares of the stock are short sold.
View Moderna's Short Interest
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its earnings results on Thursday, February, 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative trailing twelve-month return on equity of 10.23%. The company's quarterly revenue was down 44.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.61 EPS.

What guidance has Moderna issued on next quarter's earnings?

Moderna updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.97%), Vanguard Group Inc. (8.89%), Capital World Investors (0.95%), The Manufacturers Life Insurance Company (0.93%), Norges Bank (0.92%) and Coatue Management LLC (0.86%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 2/26/2024 by MarketBeat.com Staff